News
Interview: Hua Medicine receives payment from Bayer

 Hello XXXX, I wanted to offer you a unique interview opportunity with top executives at Hua Medicine (HK:2552), the company that developed and brought to the market a new ‘smart’ drug that can send diabetes into remission. The drug dorzagliatin, marketed as HuaTangNing ...

News
HUA230818-Milestone emailGL

SUBJECT: Interview – Hua Medicine achieves key milestone

News
Hua Medicine pushes ahead with next-gen diabetes treatment

More than 783 million people around the world will suffer from diabetes by 2045, 46% more than in 2021. They all need and deserve a treatment that addresses the root causes of diabetes.

News
Hua Medicine at J.P. Morgan Healthcare Conference

More than 783 million people around the world will suffer from diabetes by 2045, up 46% from 2021 levels. There is a need for a new and better approach to tackle diabetes.

News
MILESTONE PAYMENT

The Company is pleased to announce that, on 22 November 2023, Hua Shanghai received the milestone payment of RMB800 million from Bayer

News
Hua Medicine at Jefferies 4th Asia Forum with strengthened cash position

With plenty of cash on hand and new data showing the impact of its drug dorzagliatin, Hua Medicine (HKEx:2552) is presenting at the Jefferies 4th Asia Forum in Hong Kong on September 8, 2023 this week.

News
Revolutionizing Diabetes Treatment in the US: Exclusive Interview Opportunity with Innovative Biotech Hua Medicine

In an exciting development for diabetes patients, trailblazing biotech company Hua Medicine is preparing to start a clinical trial in the United States for its global first-in-class diabetes drug dorzagliatin. The US FDA accepted Hua Medicine’s IND application for the se...

News
Interview: Hua Medicine receives payment from Bayer

 Hello XXXX, I wanted to offer you a unique interview opportunity with top executives at Hua Medicine (HK:2552), the company that developed and brought to the market a new ‘smart’ drug that can send diabetes into remission. The drug dorzagliatin, marketed as HuaTangNing ...

News
HUA230818-Milestone emailGL

SUBJECT: Interview – Hua Medicine achieves key milestone

News
Hua Medicine pushes ahead with next-gen diabetes treatment

More than 783 million people around the world will suffer from diabetes by 2045, 46% more than in 2021. They all need and deserve a treatment that addresses the root causes of diabetes.

News
Hua Medicine at J.P. Morgan Healthcare Conference

More than 783 million people around the world will suffer from diabetes by 2045, up 46% from 2021 levels. There is a need for a new and better approach to tackle diabetes.

News
MILESTONE PAYMENT

The Company is pleased to announce that, on 22 November 2023, Hua Shanghai received the milestone payment of RMB800 million from Bayer

News
Hua Medicine at Jefferies 4th Asia Forum with strengthened cash position

With plenty of cash on hand and new data showing the impact of its drug dorzagliatin, Hua Medicine (HKEx:2552) is presenting at the Jefferies 4th Asia Forum in Hong Kong on September 8, 2023 this week.

Powered by